Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls

Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls

Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is relevant to beneficial tumor response and surgical down-staging in patients of GCTB. However, these trials or case series have...

Full description

Bibliographic Details
Main Authors: Hengyuan Li, Junjie Gao, Youshui Gao, Nong Lin, Minghao Zheng, Zhaoming Ye
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
giant cell tumor of bone
denosumab
local recurrence risk
malignant transformation
H3F3A G34W
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.580605/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.580605/full

Similar Items